Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, June 19, 2024 | Back issues
Courthouse News Service Courthouse News Service


MANHATTAN — Days after reaching a $495 million settlement with the United States about its Medicaid classification of EpiPens, Mylan faces a federal class action alleging securities fraud. The drugmaker has been hounded of late by consumers and Congress over EpiPen price-gouging.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.